Notice of Allowability	Application No.	Applicant(s)
	09/701,001 Examiner	ONO ET AL. Art Unit
	David A. Saunders, PhD	1644
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT I of the Office or upon petition by the applicant. See 37 CFR 1.31	pears on the cover sheet with to S (OR REMAINS) CLOSED in thi 5) or other appropriate communic RIGHTS. This application is subj	s application. If not included ation will be mailed in due course. THIS
1. \boxtimes This communication is responsive to <u>follows the Communication</u>	nication Re; Appeal, mailed 6/22/	<u>05</u> .
2. The allowed claim(s) is/are 3.4 and 31-34.		
3. A The drawings filed on 22 November 2000 are accepted b	y the Examiner.	
 4. Acknowledgment is made of a claim for foreign priority of a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority of International Bureau (PCT Rule 17.2(a)). 	ve been received. ve been received in Application N	o
* Certified copies not received:	•	
Applicant has THREE MONTHS FROM THE "MAILING DATE noted below. Failure to timely comply will result in ABANDON THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		eply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be subi INFORMAL PATENT APPLICATION (PTO-152) which give		
6. CORRECTED DRAWINGS (as "replacement sheets") mu	ust be submitted.	•
(a) \square including changes required by the Notice of Draftspe	rson's Patent Drawing Review (F	PTO-948) attached
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examine Paper No./Mail Date	r's Amendment / Comment or in t	the Office action of
Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in	1.84(c)) should be written on the d the header according to 37 CFR 1.	rawings in the front (not the back) of 121(d).
7. DEPOSIT OF and/or INFORMATION about the dep attached Examiner's comment regarding REQUIREMENT		
Attachment(s)	- -	
1. Notice of References Cited (PTO-892)	_	nal Patent Application (PTO-152)
 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB. 	Paper No./Ma	l Date <u>7/6/05</u> .
Paper No./Mail Date	,	
4. Examiner's Comment Regarding Requirement for Deposit		tement of Reasons for Allowance
of Biological Material	9. Other	
	•	

Application/Control Number: 09/701,001

Art Unit: 1644

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Cancelled claims 1-2 and 5-30, in accord with MPEP 1215.04.

The following is an examiner's statement of reasons for allowance:

Claims 3-4 and there dependents are allowable over the prior art cited in the actions of 3/5/03 and 5/11/04. It is noted that Kazanori et al teach a cell separation device which would, at the most, include the V-region of only the L-chain or the V-region of only the L-chain (see claims 1 and 2 at page 4/38 of the translation). It is noted that the invention of instant claims 3 and 4, to the contrary, would require CDRs from the V-regions of both the H- and L-chains of an anti-CD4 antibody.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Okarma (6,143,508) teaches polystyrene fiber based cell separation devices and the advantages of fibers, compared to sheets, within the devices; see col. 19, line 65-col. 20, line 67.

Application/Control Number: 09/701,001

Art Unit: 1644

The teachings of Okarma would encompass devices containing anti-CD4 monoclonal antibodies; see col. 18, lines 23-41. Neither this reference nor any of record would provide motivation to use single chain or chimeric antibodies, in lieu of monoclonal antibodies, in such devices.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A. Saunders, PhD whose telephone number is 571-272-0849. The examiner can normally be reached on Mon.-Thu., 8:00 am-5:30 pm and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free David a Saunders

Typed 7/22/05 DAS